Here are the 10-K annual reports from Zura Bio Limited (ZURA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. It highlights three in-licensed antibody programs: tibulizumab (ZB-106), crebankitug (ZB-168) and torudokimab (ZB-880), all sourced from large pharma partners.
Tibulizumab, a bispecific antibody targeting IL-17A and BAFF, is in two global Phase 2 trials: TibuSHIELD in hidradenitis suppurativa, with topline 16-week data planned for the fourth quarter of 2026, and TibuSURE in diffuse cutaneous systemic sclerosis, with topline 24-week data expected in the first half of 2027.
The filing describes earlier Phase 1 safety and pharmacodynamic data for all three assets, fully outsourced cGMP manufacturing, and composition-of-matter patents generally extending into 2031–2037. It also details substantial milestone and royalty obligations under licenses with Lilly and Pfizer, a Lonza gene-expression license, WuXi Biologics agreements, and a 2025 Athanor letter agreement that included issuing 8,657,402 shares plus cash and future sales-based obligations.